61689-35-8

Basic information

• Product Name: 1,2,4-Thiadiazole-3-carboxylicacid, 5-phenyl-, ethyl ester
• CAS NO: 61689-35-8
• Molecular Formula: C11H10 N2 O2 S
• Molecular Weight: 234.279
• Mol File: 61689-35-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1,2,4-Thiadiazole-3-carboxylicacid, 5-phenyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,4-Thiadiazole-3-carboxylicacid, 5-phenyl-, ethyl ester(61689-35-8)
• EPA Substance Registry System: 1,2,4-Thiadiazole-3-carboxylicacid, 5-phenyl-, ethyl ester(61689-35-8)

Safety Data

• Hazardous Substances Data: 61689-35-8(Hazardous Substances Data)

Usage

Classification

Carboxylic acid ester

Structure

Contains a thiadiazole ring with a phenyl group attached to the 5-position

Applications

a. Building block in the synthesis of various pharmaceuticals and agrochemicals
b. Potential applications in materials science and organic electronics

Safety precautions

Handle and use with caution due to potential hazards to human health and the environment

Upstream product

• 61689-40-5 2-oxo[1,3,4]oxathiazole-5-carboxylic acid ethyl ester 
• 100-47-0 benzonitrile 
• 101495-56-1 3-chloro-5-phenyl-[1,2,4]thiadiazole 
• 141-78-6 ethyl acetate 

Downstream Products

• 1476847-66-1 2-Methoxy-6-(6-methoxy-4-((5-phenyl-1,2,4-thiadiazol-3-yl)methoxy)benzofuran-2-yl)imidazo[2,1-b][1,3,4]thiadiazole 

Relevant articles and documents

PAR4 AGONIST PEPTIDES

The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

Non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Study of structural requirements for thiadiazolidinone derivatives

The 2,4-disubstituted thiadiazolidinones (TDZD) were described as the first non-ATP competitive GSK-3β inhibitors. New modifications in this heterocyclic ring are here reported to study the influence on the biological activity. The basic skeleton of 1,2,4-thiadiazole and also one of the carbonyl groups are kept, while different modifications are introduced in positions 3 and 5, respectively. The GSK-3β activity of the new thiadiazole derivatives here synthesized showed IC50 values for some of the compounds in the micromolar range. Additionally, ATP competition studies have been carried out, showing that as well as the first generation of TDZD, these new compounds act in a non-competitive manner. With this study, additional requirements for the biological activity of the TDZD family have been delineated.